NEW YORK — Genetic testing firm Menadna said Monday that it has become Nebula Genomics' exclusive partner in Jordan, Oman, and Iraq.
Under the terms of the deal, the companies will join Nebula's whole-genome sequencing and genetic reporting technologies with Menadna's bioinformatics capabilities to provide genomic testing to customers in the Middle East markets.
Financial and other terms of the deal were not disclosed.
"Less than 2 percent of genomic data available today comes from [Jordan, Oman and Iraq] despite its rich genetic diversity," Menadna CEO Bassam El Fahmawi said in a statement. "Our joint efforts will not only enhance patient care but also significantly contribute to the global understanding of genetic variations and their impact on health."
San Francisco-based Nebula was founded by Harvard University researcher George Church in 2017 to offer personal whole-genome sequencing testing and diagnostic-ready data. It was acquired by ProPhase Labs in mid-2021 for $14.6 million in cash and stock.
Menadna, based in Pleasanton, California, also offers whole-genome sequencing tests and wellness reports based on customers' genetic data, with a focus on the Middle East and North Africa.